Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM: Bevacizumab with or without Erlotinib maintenance in metastatic colorectal cancer
NCT00265824Phase 3Completed
- Sponsor
- GERCOR
- Start
- May 2005
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of erlotinib in colorectal cancer (metastatic) (mCRC), sponsored by GERCOR. Started May 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00265824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265824.